<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489863</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201703338 -A</org_study_id>
    <nct_id>NCT03489863</nct_id>
  </id_info>
  <brief_title>Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study</brief_title>
  <official_title>Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scott R. MacKenzie Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polymorphisms of the cytochrome P450 (CYP) 2C19 enzyme has been consistently shown to&#xD;
      modulate clopidogrel response. Accordingly, the Food and Drug Administration (FDA) has issued&#xD;
      a warning on the potential for reduced efficacy of clopidogrel among carriers of&#xD;
      loss-of-function alleles (LOF) for CYP2C19 and suggest considering alternative antiplatelet&#xD;
      therapies for these individuals.&#xD;
&#xD;
      The pharmacodynamic (PD) effects of prasugrel and ticagrelor are not affected by CYP2C19&#xD;
      genetic polymorphisms. However, to date there are no head-to-head PD comparisons between&#xD;
      these agents among patients with different CYP2C19 genetic polymorphisms, which is currently&#xD;
      under investigation in CAD patients undergoing PCI at UF Health-Jacksonville (UFJ 2014-12,&#xD;
      NCT 02065479). In order to rule out play of chance findings, pharmacogenetic investigations&#xD;
      require external validation cohorts to support the study findings. Therefore, the present&#xD;
      randomized study is designed to serve as an external validation cohort conducted in patients&#xD;
      with established CAD not undergoing PCI testing the non-inferiority in platelet reactivity of&#xD;
      prasugrel versus ticagrelor among CYP2C19 LOF allele carriers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therapeutic inhibition of platelet activation is essential for the management of ischemic&#xD;
      cardiovascular disease. The use of platelet adenosine diphosphate (ADP) P2Y12 receptor&#xD;
      antagonists (clopidogrel, prasugrel, and ticagrelor) in addition to aspirin are associated&#xD;
      with a decrease in cardiovascular events in high-risk coronary artery disease (CAD) patients.&#xD;
      Clopidogrel is the most broadly utilized P2Y12 receptor antagonist. However, among&#xD;
      clopidogrel treated patients, there is broad variability in antiplatelet drug response which&#xD;
      is known carry prognostic implications. Polymorphisms of the cytochrome P450 (CYP) 2C19&#xD;
      enzyme has been consistently shown to modulate clopidogrel response. Accordingly, the Food&#xD;
      and Drug Administration (FDA) has issued a warning on the potential for reduced efficacy of&#xD;
      clopidogrel among carriers of loss-of-function alleles (LOF) for CYP2C19 and suggest&#xD;
      considering alternative antiplatelet therapies for these individuals.&#xD;
&#xD;
      The pharmacodynamic (PD) effects of prasugrel and ticagrelor are not affected by CYP2C19&#xD;
      genetic polymorphisms. However, to date there are no head-to-head PD comparisons between&#xD;
      these agents among patients with different CYP2C19 genetic polymorphisms which is currently&#xD;
      under investigation in CAD patients undergoing PCI at UF Health-Jacksonville (UFJ 2014-12,&#xD;
      NCT 02065479). In order to rule out play of chance findings, pharmacogenetic investigations&#xD;
      require external validation cohorts to support the study findings. Therefore, the present&#xD;
      randomized study is designed to serve as an external validation cohort conducted in patients&#xD;
      with established CAD not undergoing PCI testing the non-inferiority in platelet reactivity of&#xD;
      prasugrel versus ticagrelor among CYP2C19 LOF allele carriers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Actual">March 20, 2019</completion_date>
  <primary_completion_date type="Actual">March 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P2Y12 Reaction Unit (PRU)</measure>
    <time_frame>at 24 hours post loading dose</time_frame>
    <description>Platelet reactivity measured by VerifyNow and reported as PRU</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Maintenance dose will be maintained for 10±3 days.</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Maintenance dose will be maintained for 10±3 days.</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with CAD [defined as the presence of at least a 50% stenosis in a major&#xD;
             epicardial vessel or major branch, or any prior coronary revascularization (PCI or&#xD;
             coronary bypass graft surgery)] on treatment with either aspirin (81mg/day) or aspirin&#xD;
             and clopidogrel (75m/day) for at least 30 days as per standard of care&#xD;
&#xD;
          -  Participated in UFJ 2016-14 study with genetic buccal swab test and have at least one&#xD;
             CYP 2C19 LOF allele (CYP2C19*2 and CYP2C19*3)&#xD;
&#xD;
          -  Women of childbearing age must use reliable birth control (i.e. oral contraceptives)&#xD;
             while participating in the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known allergies to prasugrel or ticagrelor&#xD;
&#xD;
          -  Weight &lt;60kg&#xD;
&#xD;
          -  Considered at high risk for bleeding&#xD;
&#xD;
          -  Currently active bleeding&#xD;
&#xD;
          -  History of ischemic or hemorrhagic stroke or transient ischemic attack, or&#xD;
             intracranial hemorrhage&#xD;
&#xD;
          -  Known severe hepatic dysfunction&#xD;
&#xD;
          -  On treatment with oral anticoagulant therapy (Vitamin K antagonists, dabigatran,&#xD;
             apixaban, rivaroxaban)&#xD;
&#xD;
          -  Platelet count &lt;80x106/mL&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dL.&#xD;
&#xD;
          -  Creatinine Clearance &lt;30 mL/minute&#xD;
&#xD;
          -  Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker&#xD;
             protection.&#xD;
&#xD;
          -  Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction&#xD;
             with ticagrelor): CYP3A Inhibitors (ketoconazole, itraconazole, voriconazole,&#xD;
             clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir,&#xD;
             and telithromycin ) and CYP3A Inducers (rifampin, phenytoin, carbamazepine, and&#xD;
             phenobarbital)&#xD;
&#xD;
          -  Pregnant or breastfeeding females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominick J Angiolillo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <results_first_submitted>August 7, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2020</results_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clopidogrel</keyword>
  <keyword>prasugrel</keyword>
  <keyword>ticagrelor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03489863/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prasugrel</title>
          <description>Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).&#xD;
Prasugrel: Maintenance dose will be maintained for 10±3 days.</description>
        </group>
        <group group_id="P2">
          <title>Ticagrelor</title>
          <description>Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).&#xD;
Ticagrelor: Maintenance dose will be maintained for 10±3 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prasugrel</title>
          <description>Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).&#xD;
Prasugrel: Maintenance dose will be maintained for 10±3 days.</description>
        </group>
        <group group_id="B2">
          <title>Ticagrelor</title>
          <description>Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).&#xD;
Ticagrelor: Maintenance dose will be maintained for 10±3 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="8"/>
                    <measurement group_id="B2" value="60" spread="8"/>
                    <measurement group_id="B3" value="59" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>diabetes mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>P2Y12 Reaction Unit (PRU)</title>
        <description>Platelet reactivity measured by VerifyNow and reported as PRU</description>
        <time_frame>at 24 hours post loading dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).&#xD;
Prasugrel: Maintenance dose will be maintained for 10±3 days.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).&#xD;
Ticagrelor: Maintenance dose will be maintained for 10±3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>P2Y12 Reaction Unit (PRU)</title>
          <description>Platelet reactivity measured by VerifyNow and reported as PRU</description>
          <units>PRU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="10"/>
                    <measurement group_id="O2" value="24" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary endpoint is non-inferiority in PRU, at 24 hours of prasugrel versus ticagrelor. Under the assumption of 0 difference at 24 hours in mean PRU between ticagrelor and prasugrel and a common standard deviation of 50 PRU, a sample size of 22 patients per group allows for the 95% CI to stay within ± 45 PRU with a 90% power and alpha = 0.05.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>see above</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prasugrel</title>
          <description>Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).&#xD;
Prasugrel: Maintenance dose will be maintained for 10±3 days.</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelor</title>
          <description>Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).&#xD;
Ticagrelor: Maintenance dose will be maintained for 10±3 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dominick J. Angiolillo</name_or_title>
      <organization>University of Florida College of Medicine Jacksonville</organization>
      <phone>9042443378</phone>
      <email>dominick.angiolillo@jax.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

